Examkin

Soru

Zorluk: ZorDiagnostic Workup and Test Sequencing

A 6262-year-old man comes to the clinic to establish care. His past medical history is significant for essential hypertension, hyperlipidemia, and a 3030-pack-year smoking history; he quit smoking 1010 years ago. He currently has no respiratory complaints, weight loss, night sweats, or hemoptysis. Vital signs are within normal limits. Physical examination reveals clear lung fields bilaterally and no palpable cervical or supraclavicular lymphadenopathy. A chest radiograph obtained during a recent health fair revealed a small opacity in the right mid-lung zone. He is referred for a high-resolution, non-contrast computed tomography (CT) scan of the chest, which reveals a 1313-mm solid, non-calcified pulmonary nodule with smooth margins in the right middle lobe. No hilar or mediastinal lymphadenopathy is identified. Medical records from his previous provider are requested, but no prior imaging studies are available for comparison. Which of the following is the most appropriate next step in the diagnostic workup?

  1. Positron emission tomography scanCevap
  2. B
    Percutaneous computed tomography-guided core needle biopsy
  3. C
    Repeat computed tomography scan of the chest in 3 months
  4. D
    Video-assisted thoracoscopic surgery
  5. E
    Magnetic resonance imaging of the chest

Cevap

Positron emission tomography scan
The correct diagnostic test is a positron emission tomography (PET) scan. The evaluation of a solitary pulmonary nodule (SPN) involves estimating the clinical probability of malignancy based on patient risk factors (age, smoking history, occupational exposures) and radiographic characteristics (size, margins, location, calcification). This patient presents with a 1313-mm solid nodule without benign calcifications. Given his age (6262 years) and significant smoking history, his pretest probability of malignancy is intermediate (typically 5%5\% to 65%65\%). According to current evidence-based guidelines (e.g., American College of Chest Physicians), the standard test sequence for an indeterminate solid nodule >8>8 mm in an intermediate-risk patient is a fluorodeoxyglucose (FDG)-PET scan. A highly avid nodule on PET would warrant definitive tissue diagnosis via biopsy or surgical excision, whereas a metabolically 'cold' nodule can be managed with serial CT surveillance.

Adım Adım Çözüm

1
Analyze the nodule characteristics and patient demographics.
The nodule is solid, 1313 mm in size, without benign calcification patterns. The patient is 6262 years old with a 3030-pack-year smoking history.
Solitary pulmonary nodules require risk stratification to determine the correct sequence of diagnostic testing.
2
Stratify the clinical probability of malignancy.
The patient falls into the intermediate risk category (typically 5%5\% to 65%65\%). High risk would be characterized by a larger size (e.g., >15>15 mm), spiculation, or active smoking. Low risk would be younger patients with no smoking history and smaller nodules.
Guidelines strictly dictate the next diagnostic step based on the assigned pretest probability bracket.
3
Select the guideline-indicated next step for an intermediate-risk solid nodule measuring >8>8 mm.
Positron emission tomography (PET) scan.
Functional imaging with PET safely differentiates benign from malignant lesions in the intermediate-risk group, optimizing the decision between invasive biopsy/resection and conservative CT surveillance.

Anahtar Kavram

Diagnostic sequencing for a solitary pulmonary nodule relies on pretest probability stratification; solid indeterminate nodules >8>8 mm with an intermediate risk of malignancy require functional assessment with a PET scan before proceeding to invasive biopsy or conservative surveillance.
Bu soruyu puanla

Konular

Diagnostic Workup and Test Sequencing

Bu konudan daha fazla soru